CCR2 and metabolic dysfunction-associated steatohepatitis: CVC, a dual, potent CCR2 and CCR5 inhibitor, has demonstrated its effect on mitigating inflammatory pathways in both HIV-1 patients and patients with NASH along with decreasing HIV-1 RNA [25,27,28].